9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)
Jahanzeb M, Fischbach N, Kosty M, Kumar P, Spigel D, Wozniak A, Teng S, Wang L, Sing A, Lynch T. 9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS). European Journal Of Cancer Supplements 2009, 7: 507. DOI: 10.1016/s1359-6349(09)71719-7.Peer-Reviewed Original ResearchPreliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS)
Fischbach N, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). Journal Of Clinical Oncology 2009, 27: 8040-8040. DOI: 10.1200/jco.2009.27.15_suppl.8040.Peer-Reviewed Original ResearchNon-small cell lung cancerObservational cohort studyAdverse eventsClinical outcomesNSCLC ptsAdvanced non-small cell lung cancerARIES observational cohort studyMedian f/uAnti-VEGF monoclonal antibodyKey safety outcomeProtocol-specified treatmentSafety of bevacizumabCarboplatin/paclitaxelSerious adverse eventsPhase III trialsEffectiveness of bevacizumabCell lung cancerSubpopulation of patientsCohort sizePoor PSBrain metastasesChemotherapy regimenBaseline characteristicsCohort studyIII trials